Superiority of the Triple-Acting 5-HT(6)R/5-HT(3)R Antagonist and MAO-B Reversible Inhibitor PZ-1922 over 5-HT(6)R Antagonist Intepirdine in Alleviation of Cognitive Deficits in Rats

[Image: see text] The multifactorial origin and neurochemistry of Alzheimer’s disease (AD) call for the development of multitarget treatment strategies. We report a first-in-class triple acting compound that targets serotonin type 6 and 3 receptors (5-HT-Rs) and monoamine oxidase type B (MAO-B) as a...

Descripción completa

Detalles Bibliográficos
Autores principales: Grychowska, Katarzyna, López-Sánchez, Uriel, Vitalis, Mathieu, Canet, Geoffrey, Satała, Grzegorz, Olejarz-Maciej, Agnieszka, Gołębiowska, Joanna, Kurczab, Rafał, Pietruś, Wojciech, Kubacka, Monika, Moreau, Christophe, Walczak, Maria, Blicharz-Futera, Klaudia, Bento, Ophélie, Bantreil, Xavier, Subra, Gilles, Bojarski, Andrzej J., Lamaty, Frédéric, Becamel, Carine, Zussy, Charleine, Chaumont-Dubel, Séverine, Popik, Piotr, Nury, Hugues, Marin, Philippe, Givalois, Laurent, Zajdel, Paweł
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10641814/
https://www.ncbi.nlm.nih.gov/pubmed/37797083
http://dx.doi.org/10.1021/acs.jmedchem.3c01482

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10641814/
https://www.ncbi.nlm.nih.gov/pubmed/37797083
http://dx.doi.org/10.1021/acs.jmedchem.3c01482

Ejemplares similares